帕博利珠单抗致免疫相关性不良反应文献回顾性分析

目的：分析帕博利珠单抗药品不良反应(Adverse Drug Reactions，ADR)的发生情况和临床特点，为临床合理用药提供参考。方法：检索中国知网、万方、维普、PubMed、Springer及Wiley中关于帕博利珠单抗的ADR个案报道，对其进行统计和分析。结果：帕博利珠单抗致ADR个案报道共41篇53例。 患者的年龄主要为51~70岁(54.71%)。ADR多发生在用药3个月后(47.37%)，以皮肤系统(47.37%) 损害多见。ADR主要表现为大疱性类天疱疮(8例次)和视力下降(5例次)等。结论：在临床使用帕博利珠单抗时应注意监测和防治其ADR，避免严重的ADR发生。

Retrospective Analysis to Literature of Immune-related Adverse Drug Reactions of Pabolizumab

To analyze the occurrence and clinical characteristics of Adverse Drug Reactions (ADR) of pabolizumab, and provide references for the rational use of drugs in clinical practice. Methods: Literature related to adverse reaction case reports of pabolizumab in CNKI database, Wanfang database, VIP database, PubMed, Springer and Wiley were searched for statistics and analysis. Results: There were 41 reports and 53 cases of ADR induced by Pabolizumab in the literature. The age of the patients was mainly from 51 to 70 years old (54.71%). ADR mostly occurred after 3 months of medication (47.37%), and damage to the skin system (47.37%) was more common. The main manifestaftions of ADR were bullous pemphigoid (8 cases) and decreased vision (5 cases). Conclusion: In clinical use of pabolizumab, attentions should be paid to the monitoring and prevention of its ADR so as to avoid the occurrence of severe ADR.